Pharmacologic Management of Non-Alcoholic Fatty Liver Disease

George Boon-Bee Goh*, Srinivasa Dasarathy and Arthur McCullough
Departments of Gastroenterology, Cleveland Clinic Foundation 9500 Euclid Avenue/ A30 Cleveland, OH 44195, USA

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common complex chronic liver disease that encompasses a spectrum of disease from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH has the potential to progress to advanced fibrosis and cirrhosis and is associated with increased morbidity and mortality. Currently, there are no definitive universally accepted treatment options available for NASH. Most pharmacological agents that have been investigated are limited by inconsistent efficacy or side effects. We reviewed the current literature on the principle drugs that have been tested for NAFLD in the adult population, with special emphasis on clinical data and safety profiles.

Methods: A comprehensive PUBMED/MEDLINE search was conducted to identify principal therapeutic intervention studies for NAFLD, from which a summary of the studies were formulated in this review.

Results: A variety of studies, including retrospective, open-label and randomised controlled trials were reviewed in terms of clinical efficacy and side effect profiles. In addition to the most commonly studied therapeutic agents (insulin sensitizers, vitamin E, pioglitazone, UDCA, PUFAs, statins and ezetimibe), emerging pharmacologic agents showing potential efficacy in NAFLD were also explored.

Conclusion: Based on risk-benefit profiles, pioglitazone seems to have the best treatment outcomes currently, with significant improvement in histology while having minimal tolerable side effects. Further clinical research is warranted to understand and improve our repertoire of treatment options, including potential combination therapy, towards this complex disease.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, with disease prevalence of approximately 35% [1,2]. It represents a clinicopathologic disease entity ranging from simple steatosis (SS), which has a relatively benign course to non-alcoholic steatohepatitis (NASH), where hepatic steatosis is accompanied by significant necroinflammation, hepatocyte injury (ballooning) with or without fibrosis [3]. Patients with NASH are at risk of disease progression and complications; 38% of patients with NASH will have progression of fibrosis in 5 years and 20% will develop cirrhosis over 10 years [4]. In addition, relative to SS or the general population, patients with NASH are at risk of increased mortality, particularly liver related or cardiovascular related mortality [5-7]. Indeed, NAFLD is anticipated to become the leading cause of liver transplantation in the near future [8]. Consequently, there is a pressing need to address this disease in terms of effective and safe treatment options. However, 34 years after the first description by Ludwig et al. [9], NAFLD remains a difficult disease to manage, with no universally accepted pharmacologic treatment options currently available. Lifestyle modification involving diet restriction, weight loss and exercise is often suggested as the first line therapy for NAFLD, but is difficult to maintain on a long term basis. As such, pharmacologic options are then indicated. We reviewed the current literature on the principle drugs that have been tested for NAFLD in the adult population, with special emphasis on clinical efficacy and safety profiles.

Insulin sensitizers

Given that insulin resistance (IR) plays a dominant role in the pathogenesis of NAFLD, insulin sensitizers have been extensively explored as treatment options, the principle agents being metformin and thiazolidinediones (TZD).

Metformin

Metformin is a biguanide widely used in clinical practice and has been used since the 1950s, but only gained FDA approval in 1994 [10]. It is the first line oral therapy agent for the treatment of type 2 diabetes mellitus (DM), as recommended by American and European diabetes association [11]. Metformin improves insulin sensitivity via inhibition of gluconeogenesis, stimulating glucose uptake in muscles, inhibiting adipose tissue lipolysis and augmenting hepatic fatty acid oxidation [12]. Animal studies first demonstrated the reversal of hepatic steatosis, liver inflammation and ALT abnormalities with metformin [13,14]. Among the first non-randomised clinical trials, Marchesini observed that metformin improved aminotransferases [15]. Subsequent studies supported the beneficial role of metformin on liver biochemistry and metabolic profiles, but effect of metformin on liver histology remained limited and inconsistent [16]. In particular, metformin did not show improvement of liver histology in randomised trials [16]. As summarised in Table 1, thirteen studies involving metformin in NAFLD have been performed, with variable effects seen in liver enzymes, metabolic parameters and liver histology. Several meta-analyses have also been conducted. Rakosi et al. observed that metformin had no beneficial pooled effects on liver histology, ALT...
The FLIRT trial confirmed the effect of rosiglitazone on liver aminotransferase and steatosis, but also did not demonstrate improvement on fibrosis [24]. Furthermore, extension of treatment with rosiglitazone did not improve liver histology [26]. Other studies have focused on pioglitazones, which also reported efficacy in improving aminotransaminases but variable effects on liver histology [27,28]. In the landmark PIVENs trials with the largest number of NAFLD patients in a treatment trial, pioglitazone was associated with decreased aminotransaminases, reduction of hepatic steatosis and lobular inflammation, but not fibrosis. However, the histological improvements did not attain the prespecified level of significance for primary histological outcome [29]. The principal trials of TZDs in NAFLD are illustrated in Table 2. Meta-analysis of studies evaluating TZDns in NAFLD showed consistently that TZDns improved steatosis, ballooning and inflammation [17,18,30,31], while only one meta-analysis showed improvement in fibrosis [31]. Improvement in fibrosis was also seen in another meta-analysis when trials focusing specifically on pioglitazones were analysed [30]. However, the drawbacks of TZD therapy are also considerable. The beneficial effects of TZDns are not maintained with discontinuation of therapy, suggesting the need for continued long term therapy [32]. In addition, the safety of sustained TZN use has also been questioned. Increased risk of edema [33] and heart failure [34] have been reported with TZN usage. An increased risk of cardiovascular events was seen with rosiglitazone [35] but not with pioglitazone [36] leading to restrictions on the usage of rosiglitazone in clinical practice. Other pertinent considerations include weight gain [average weight gain of 4.4 kg [31], bone loss with increased risk of fractures [37] and increased risk of bladder cancers [38]. Consequently, there are reservations in recommending TZDns as a major therapeutic option.

### Antioxidants & cytoprotective agents

**Antioxidants:** Oxidative stress and accompanying...
proinflammatory cytokines have been recognised as an important aspect of NASH pathogenesis. Hence, several studies of antioxidants have been conducted in NAFLD, with the most commonly studied antioxidant agent being vitamin E. Multiple studies of vitamin E either alone or in combination with other agents have been performed with generally beneficial results Table 3. The largest trial was the PIVENS trial with 247 non-diabetic NASH patients, which showed that 800 IU of vitamin E improved aminotransaminases, hepatic steatosis and inflammation, but had no effect on fibrosis [29]. A separate randomised controlled study demonstrated that a combination of vitamin E and C improved histological fibrosis scores but not histological inflammation or ALT [39]. Of concern, however, high dose vitamin E (400 iu or more) has been implicated in increased all-cause mortality in one meta-analysis [40], which was not observed in other meta-analysis [41,42]. Furthermore, a separate meta-analysis observed that vitamin E might be associated with increased risk for hemorrhagic stroke [43], while the SELECT trial suggested an increased incidence of prostate cancer in healthy men taking 400 iu of vitamin E daily over 7 years [44]. Accordingly, the enthusiasm for vitamin E has been tempered by concerns over safety with long term use of vitamin E. Nevertheless, vitamin E can still be considered as a treatment option in non-diabetic patients with NASH, as suggested by the guidelines of the American Association for the Study of Liver Diseases (3).

Pentoxifylline: Pentoxifylline is a non-selective phosphodiesterase inhibitor with anti-inflammatory properties via TNF-a inhibition. Few randomised, placebo controlled trials on patients with NASH have been conducted, most with favourable results Table 3. In a small pilot study, Lee et al. found that while pentoxifylline, there was no effect on the inflammatory markers -TNF-a and IL-6. However, this study was limited by a small sample size and short duration of treatment [45]. A separate trial found no significant benefit of pentoxifylline on aminotransaminases or liver histology [46]. In contrast, Zein et al. found that pentoxifylline improved NAFLD activity scores, steatosis, inflammation and fibrosis, but not ballooning [47]. A recent meta-analysis of 5 randomised trials found that pentoxifylline reduced aminotransaminases, steatosis, inflammation and fibrosis [48]. In terms of safety profile, only minor side effects were reported with pentoxifylline. These include nausea, emesis, headaches and abdominal cramps, which did not usually require treatment discontinuation [46,47].

Polyunsaturated fatty acids: N-3 polyunsaturated fatty acids (PUFA) are essential fatty acids that can only be derived from exogenous sources. Some data suggest that a low dietary intake of PUFA may have a role in NAFLD pathogenesis [49]. In addition, PUFA has been shown to improve hypertension, dyslipidemia and cardiovascular disease [50], diseases closely related to NAFLD [51]. PUFA act by regulating gene transcription factors involved in hepatic lipid metabolism [52] which have down-stream effects of increased insulin sensitivity, inhibition of hepatic lipogenesis, increased fatty acid oxidation and reduction of pro-inflammatory cytokines [53]. Various studies using a range of PUFA dosages, composition of the PUFA and duration of treatment have not found consistent results in the context of NAFLD Table 4 [53]. More importantly, most of the studies did not evaluate histological endpoints of treatment. Among the first trials, Capanni et al. found that PUFA improved liver aminotransaminases, metabolic profiles and hepatic steatosis on imaging [54]. Other studies have provided collaborative observations [53]. A meta-analysis of 9 trials and 355 patients found that there were beneficial changes in hepatic steatosis but less convincing evidence of improvement in aminotransaminases with PUFA therapy [55]. Two recent randomised controlled trials which provided histological outcome measures did not demonstrate improved liver histology, but in fact suggested worsening of insulin resistance with PUFA therapy in one trial [56,57]. More studies are required before PUFA can be recommended as a treatment option in NAFLD.

Ursodeoxycholic acid (UDCA): UDCA is a naturally occurring hydrophilic bile acid originally approved for treatment of primary biliary cirrhosis. It acts through alteration of the bile acid pool, immune modulation and reduction of oxidative stress [58]. Several studies exploring effects of UDCA monotherapy or in combination with other agents have reported improvement in aminotransaminases predominantly, with less convincing efficacy in histology Table 4 [49]. Initial UDCA monotherapy at a dose of 13-15 mg/kg did not show any efficacy on aminotransaminases or liver histology [59] while higher dose UDCA monotherapy (28-35 mg/kg) improved aminotransaminases and serum markers of fibrosis (Fibrotest), but no histologic endpoints were evaluated [60]. In combination with vitamin E, UDCA also showed mainly improvement of aminotransaminases [61,62]. In a recent meta-analysis of 3 studies involving 385 subjects, UDCA did not demonstrate any biochemical benefits in NASH. In addition, while there was improvement of lobular inflammation, there was also a suggestion that fibrosis may increase with UDCA [63]. While UDCA is generally well tolerated, with only minor gastrointestinal side effects observed, based on the limited evidence of drug efficacy, UDCA is generally not recommended in NAFLD [27,64].

Lipid lowering agents

Lipotoxicity, which is the hepatic accumulation of lipid molecules

---

**Table 3: Studies of Vitamin E and Pentoxifylline in adult NAFLD patients.**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Intervention</th>
<th>Sample size</th>
<th>Duration</th>
<th>Liver enzymes</th>
<th>Histology</th>
<th>Other endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yakaryilmaz [113]</td>
<td>Vit E</td>
<td>9</td>
<td>24 wks</td>
<td>↓ALT, AST</td>
<td>Improvement</td>
<td>↓IR</td>
</tr>
<tr>
<td>Bugianesi [98]</td>
<td>Vit E vs Diet</td>
<td>110</td>
<td>12 mths</td>
<td>Not improved</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Sanyal [29]</td>
<td>Vit E vs Plac</td>
<td>274</td>
<td>24 mths</td>
<td>↓ALT, AST</td>
<td>Improvement</td>
<td></td>
</tr>
<tr>
<td>Pietu [62]</td>
<td>Vit E+UDCA</td>
<td>101</td>
<td>4 years</td>
<td>↓ALT, AST</td>
<td>Improvement</td>
<td></td>
</tr>
<tr>
<td>Dufour [61]</td>
<td>Vit E+UDCA vs plac</td>
<td>48</td>
<td>24 mths</td>
<td>↓ALT, AST</td>
<td>Improvement</td>
<td></td>
</tr>
<tr>
<td>Harrison [39]</td>
<td>Vit E+C vs plac</td>
<td>49</td>
<td>6 mths</td>
<td>Not improved</td>
<td>Improvement</td>
<td></td>
</tr>
<tr>
<td>Foster [114]</td>
<td>Vit E/Vit C/Atorvastatin vs plac</td>
<td>1005</td>
<td>4 years</td>
<td>NA</td>
<td>NA</td>
<td>Reduced steatosis on CT</td>
</tr>
<tr>
<td>Satapathy [115]</td>
<td>Pentoxifylline</td>
<td>18</td>
<td>6 mths</td>
<td>↓ALT, AST</td>
<td>NA</td>
<td>↓IR, ↓TNF α, ↓fatigue</td>
</tr>
<tr>
<td>Satapathy [116]</td>
<td>Pentoxifylline</td>
<td>9</td>
<td>12 mths</td>
<td>↓ALT, AST</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Lee [45]</td>
<td>Pentoxifylline vs plac</td>
<td>11</td>
<td>3 mths</td>
<td>↓AST</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Van Wagner [46]</td>
<td>Pentoxifylline vs plac</td>
<td>30</td>
<td>12 mths</td>
<td>Not improved</td>
<td>Not improved</td>
<td></td>
</tr>
<tr>
<td>Zein [47]</td>
<td>Pentoxifylline vs plac</td>
<td>55</td>
<td>12 mths</td>
<td>↓ALT</td>
<td>Improvement</td>
<td></td>
</tr>
</tbody>
</table>

Vit E: vitamin E, plac: placebo, UDCA: ursodeoxycholic acid, wks: weeks, mths: months, NA: not assessed, IR: insulin resistance, TNFα: tumor necrosis factor α
that lead to inflammatory damage of hepatocytes, has emerged as an important mechanism in the pathogenesis of hepatic steatosis, steatohepatitis and fibrosis [65]. Therefore, lipid lowering therapy may improve liver disease by improving lipid profile and lowering lipotoxicity [66].

**Statins:** Statins are potent lipid lowering agents via their inhibition of hydroxymethylglutaryl-coenzyme A reductase. Besides lowering cardiovascular risk, statins also have immunomodulatory, antioxidative, anti-thrombotic and anti-inflammatory properties [67,68]. Traditionally, the concerns that statins can induce aminotransaminase elevations had limited the use of statins in liver disease. However, several studies have demonstrated the safety of statin use in NAFLD [69,70]. Moreover, several studies reported improvement in liver aminotransaminases or hepatic steatosis on treatment with statins 

**Ezetimibe:** Ezetimibe inhibits dietary cholesterol absorption from the intestinal lumen via inhibition of the sterol transporter, Niemann-Pick C1-like 1 (NPC1L1) protein, consequently leading to reduced serum cholesterol levels [75]. Studies have explored ezetimibe monotherapy or in combination with other agents such as statins and acarbose, which in general, showed improvement in aminotransaminases and lipid profile [76]. Two pilot open labelled trials demonstrated that ezetimibe improved insulin resistance, lipid profile, aminotransaminases and inflammatory markers, while also extending benefits to steatosis, necroinflammation, ballooning...
and NAS on histology. However, there was no significant effect on fibrosis [76,77]. A subsequent and only RCT to date that evaluated ezetimibe in NAFLD with post treatment histology reported significant improvement in histological ballooning and fibrosis from baseline, but there were no significant histological differences compared to placebo. In addition, ezetimibe worsen HbA1c levels [78]. Further studies are warranted to evaluate ezetimibe in NAFLD.

**Emerging Drug Therapies**

A variety of new therapeutic agents targeting various aspects of pathogenesis in NAFLD are currently emerging. Novel antidiabetic agents target the Glucagon-like peptide-1 (GLP-1) incretin pathway which regulate blood glucose by stimulation of insulin release, improve hepatic fatty acid oxidation and insulin sensitivity [79]. They include GLP-1 analogues (exenatide, liraglutide) and dipeptidyl peptidase (DPP) IV inhibitors (sitagliptin, vildagliptin, saxagliptin) which prevent the rapid degradation of GLP-1 [28]. A small open labelled case series found that exenatide improved grade of ballooning and fibrosis score in 4 out of 8 diabetic patients with NASH, accompanied by significant improvement in weight loss, diabetic profile and aminotransaminase [80]. A separate study found that liraglutide improved BMI, aminotransferases and APRI (AST to platelet ratio index) score, a surrogate non-invasive marker of hepatic fibrosis [81] To further studies investigated the use of sitagliptin, demonstrating beneficial effects ranging from reduction in BMI, aminotransferases, ballooning and NASH scores [82,83]. Another agent of increasing interest in NAFLD is the Farnesoid X receptor (FXR) agonist. Obeticholic acid (OCA) is a semisynthetic FXR agonist which can modulate hepatic lipogenesis, steatosis and insulin resistance, in addition to inhibiting inflammatory and fibrogenic responses [84]. A pilot study demonstrated that OCA was well tolerated, improved insulin sensitivity, aminotransaminases and markers of inflammation/fibrosis in diabetic subjects with NASH [85]. The Farnesoid X Receptor Ligand Obeticholic Acid in NASH treatment (FLINT) trial conducted by the NASH clinical research network investigating the use of OCA in NASH patients had recently ended and published results are currently being eagerly awaited. Another exciting agent in development is the lusily oxide-like-2 (LOXL-2) inhibitor monoclonal antibody, simtuzumab, which is an anti-fibrotic agent currently being investigated in NASH patients with advanced fibrosis/cirrhosis [49,86]. There have been a number of many other pharmacological agents with potential benefits in NAFLD. However, there are extremely limited data on the efficacy of these agents that prevent a reliable review or recommendation for their clinical use. These would include probiotics [87-89], S-Adenosylmethionine (SAMe) supplements [90,91], α-lipoic acid [92,93] and milk thistle/silybin [94,95]. Other investigatory agents can also be found at the national institute of heath website: http://clinicaltrials.gov.

**Conclusion**

NAFLD is an increasingly prevalent disease with potentially severe outcomes, yet current treatment approaches remain much to be desired. At present, no drug has universally been accepted for the treatment of NAFLD, as evidenced by the myriad of approaches explored. Most therapeutic agents do not show clear consistent efficacy or are limited by side effect profiles. Balancing these two aspects, pentoxifylline seems to have the best treatment outcomes with significant improvement in histology while having minimal tolerable side effects. Further clinical research is warranted to understand and improve our repertoire of treatment options towards this complex disease.

**References**


Atorvastatin decreases serum levels of advanced glycation endproducts in patients with non-alcoholic fatty liver patients. Aliment Pharmacol Ther 23: 1643-1647.

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 45: 750-757.

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 184: 233-234.

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 184: 233-234.